UK markets open in 5 hours 23 minutes
NIKKEI 225
39,336.00 +548.62 (+1.41%) HANG SENG
19,621.43 +67.82 (+0.35%) CRUDE OIL
79.99 -0.07 (-0.09%) GOLD FUTURES
2,435.40 +18.00 (+0.74%) DOW
40,003.59 +134.19 (+0.34%) Bitcoin GBP
52,071.95 -626.52 (-1.19%)
Lonza Group Ltd (LZAGF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:47PM EDT
| Previous close | 599.02 |
| Open | 589.52 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 573.15 - 592.64 |
| 52-week range | 336.03 - 661.60 |
| Volume | |
| Avg. volume | 241 |
| Market cap | 42.116B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 58.84 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.41 (0.76%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- PR Newswire
NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
- Business Wire
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
© 2024 Yahoo. All rights reserved.